Celsion Corporation (NASDAQ: CLSN) announced the receipt of a Fast-Track Designation from the U.S. Food and Drug Administration (FDA) for GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy that is currently undergoing Phase II trials for the treatment of advanced ovarian cancer. The candidate is an IL-12...
While Industries across the globe are grappling with the pandemic and its impact on their operations, Biotech Industry has been focused on minimizing the impact and marching ahead with its innovations and breakthroughs. We take a look at some Biotech’s that are impervious to the scare...
Aravive, Inc. (NASDAQ: ARAV), a clinical stage biotechnology Company engaged in developing therapeutics for solid tumours and hematologic malignancies, announced positive data from its ongoing Phase 1b/2 study of AVB-500, intended for treatment of Ovarian cancer patients. The results were presented at the European Society...
The American Cancer society estimates that in 2019, there will be around 22,530 new diagnoses of Ovarian Cancer and 13,980 women will succumb to the disease. It is the fifth largest cause for death in women, with over 1 in 78 chances of acquiring this...
Sjogren’s, named after its discoverer Henrik Sjögren, is the most prevalent systemic autoimmune disease that predominantly affects women. This disorder is manifested in the form of dry eyes, dry mouth, joint pains and chronic fatigue and if left untreated can cause severe dysfunction in organs...
